We are live on ! Find out more
LKFT

Lakefront Biotherapeutics American Depositary Shares

48 hedge funds and large institutions have $628M invested in Lakefront Biotherapeutics American Depositary Shares in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 2

26% more funds holding

Funds holding: 3848 (+10)

16% more capital invested

Capital invested by funds: $543M → $628M (+$85.2M)

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
48
Holders Change
+10
Holders Change %
+26.32%
% of All Funds
1.28%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
12
Increased
15
Reduced
14
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$299M +$340K +6,032 +0.1%
Federated Hermes
2
Federated Hermes
Pennsylvania
$71.3M
EC
3
EcoR1 Capital
California
$32.4M +$3.45M +61,191 +14%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$30.3M -$16.8M -298,597 -39%
O
5
OrbiMed
New York
$29.6M +$5.93M +105,200 +30%
DM
6
Deerfield Management
New York
$27.4M -$1.97M -35,000 -8%
CAM
7
Cormorant Asset Management
Massachusetts
$21.4M
Goldman Sachs
8
Goldman Sachs
New York
$18.7M -$608K -10,780 -4%
BBA
9
Baker Bros. Advisors
New York
$16.8M
RSCM
10
Rock Springs Capital Management
Maryland
$13.6M
TCM
11
Tekla Capital Management
Massachusetts
$9.55M
Renaissance Technologies
12
Renaissance Technologies
New York
$9.06M +$7.44M +132,100 +1,631%
Adage Capital Partners
13
Adage Capital Partners
Massachusetts
$5.5M -$8.45M -150,000 -64%
Deutsche Bank
14
Deutsche Bank
Germany
$4.33M +$2.93M +51,990 +348%
DCM
15
DAFNA Capital Management
California
$4.27M +$141K +2,500 +4%
Morgan Stanley
16
Morgan Stanley
New York
$4.1M +$193K +3,431 +6%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$4.08M -$136K -2,414 -4%
AA
18
ALPS Advisors
Colorado
$3.8M -$338K -5,993 -9%
EAM
19
Eventide Asset Management
Massachusetts
$3.36M
ACM
20
Atika Capital Management
New York
$3.36M +$1.75M +31,000 +148%
JGC
21
J. Goldman & Co
New York
$3.23M +$2.82M +50,000 New
CCP
22
Clough Capital Partners
Massachusetts
$3.12M -$947K -16,800 -26%
WJA
23
Williams Jones & Associates
New York
$2.89M +$55.1K +978 +2%
Northern Trust
24
Northern Trust
Illinois
$949K -$498K -8,839 -38%
WMSA
25
Weiss Multi-Strategy Advisers
New York
$841K +$240K +4,252 +49%

LKFT Hedge Fund Activity: Q3 2016 in Review

48 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q3 2016, worth a combined $628M — up 16% from $543M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new LKFT positions and 2 closed out — a net gain of 10 holders — while 15 added to existing stakes and 14 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $7.44M. The largest seller was Wellington Management Group, cutting an estimated $16.8M.

  • 48 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q3 2016, up from 38 in Q2 2016.
  • Funds reported $628M of Lakefront Biotherapeutics American Depositary Shares stock for Q3 2016, up 16% quarter-over-quarter.
  • 12 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q3 2016 and 2 closed out, a net change of +10 holders.
  • The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q3 2016 was Renaissance Technologies, an estimated $7.44M added.
  • The largest Lakefront Biotherapeutics American Depositary Shares seller in Q3 2016 was Wellington Management Group, an estimated $16.8M sold.

Based on aggregated 13F filings for Q3 2016.